Immuneering to Highlight Atebimetinib’s Broad Potential for Combinations in Pancreatic and Anaplastic Thyroid Cancers at the 2026 EORTC-NCI-AACR Symposium

On November 4, 2026 Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, reported that two abstracts evaluating atebimetinib (IMM-1-104), its lead investigational candidate designed to provide Deep Cyclic Inhibition of the MAPK pathway, have been accepted for presentation at the 2026 EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) Symposium on Molecular Targets and Cancer Therapeutics, taking place November 17–19, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentations will highlight new preclinical findings supporting the potential of atebimetinib in combination with multiple targeted therapies in pancreatic ductal adenocarcinoma (PDAC), as well as chemotherapy combinations in anaplastic thyroid cancer (ATC). The pancreatic cancer abstract has been selected for a Poster Spotlight presentation.

Presentation Details:

Pancreatic Ductal Adenocarcinoma – Poster Spotlight Presentation
Title: Patient-aligned 3D tumor models identify biomarker-enriched atebimetinib (IMM-1-104) combination strategies in pancreatic ductal adenocarcinoma
Abstract Number: 22
Poster Number: PB-003
Presenter: Anna Travesa, Immuneering Corporation
Date: November 19, 2026
Time: 14:00–14:30 CET
Session: Poster Spotlight Session

Anaplastic Thyroid Cancer – Preclinical Poster Presentation
Title: Atebimetinib, a deep cyclic inhibitor of MEK, combined with chemotherapy: preclinical rationale for treatment of anaplastic thyroid cancer (ATC)
Abstract Number: 144
Poster Number: PB-144
Presenter: Praveen Nair, Immuneering Corporation
Date: November 18, 2026
Session: Translational Studies

Following presentation, the poster will be available on the publications section of Immuneering’s website at View Source

(Press release, Immuneering, NOV 4, 2026, View Source [SID1234674201])